| 40.24 -1.87 (-4.44%) | 12-15 15:59 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 51.07 | 1-year : | 59.65 |
| Resists | First : | 43.72 | Second : | 51.07 |
| Pivot price | 39.68  |
|||
| Supports | First : | 34.54 |
Second : | 28.87 |
| MAs | MA(5) : | 40.01 |
MA(20) : | 38.43 |
| MA(100) : | 19.49 |
MA(250) : | 0 | |
| MACD | MACD : | 3.9 |
Signal : | 4.5 |
| %K %D | K(14,3) : | 64 |
D(3) : | 62.1 |
| RSI | RSI(14): 67.6 |
|||
| 52-week | High : | 43.72 | Low : | 3.72 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ COGT ] has closed below upper band by 34.4%. Bollinger Bands are 49.7% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 0 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 42.27 - 42.49 | 42.49 - 42.66 |
| Low: | 39.4 - 39.62 | 39.62 - 39.79 |
| Close: | 39.89 - 40.26 | 40.26 - 40.54 |
Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes CGT9486, a selective tyrosine kinase inhibitor designed to inhibit the KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. It has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
Mon, 15 Dec 2025
Cogent Biosciences: Time For A Pause (NASDAQ:COGT) - Seeking Alpha
Sun, 14 Dec 2025
Cogent Biosciences Stock Surged by Positive Pivotal Trial Results - StocksToTrade
Sun, 14 Dec 2025
Cogent Biosciences’ Clinical Trials Propel Stock with Promising Data - timothysykes.com
Sun, 14 Dec 2025
Frazier Life Sciences Management L.P. Grows Stake in Cogent Biosciences, Inc. $COGT - MarketBeat
Sat, 13 Dec 2025
Cogent Biosciences’ Stock Climbs with Landmark Clinical Trial Results - StocksToTrade
Tue, 09 Dec 2025
Cogent Biosciences (COGT): Valuation Check After Positive APEX Part 2 Trial Results for Bezuclastinib - Sahm
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 154 (M) |
| Shares Float | 109 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 92.2 (%) |
| Shares Short | 14,170 (K) |
| Shares Short P.Month | 15,050 (K) |
| EPS | -2.05 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.38 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -47.5 % |
| Return on Equity (ttm) | -95.5 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -1.99 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -246 (M) |
| Levered Free Cash Flow | -140 (M) |
| PE Ratio | -19.63 |
| PEG Ratio | 0 |
| Price to Book value | 28.94 |
| Price to Sales | 0 |
| Price to Cash Flow | -25.12 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|